Global Hemophilia Drugs Market Insights, Forecast to 2025

Publisher Name :
Date: 06-Jun-2019
No. of pages: 110
Inquire Before Buying

The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab' by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate' for type A and ‘Aprolix' for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.

With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market's growth over the forecast period.

The Americas led the global hemophilia drugs market in 2017 and is expected to continue its dominance until the end of 2023. The Americas have the highest revenue share in the global market with the US contributing to the majority of this revenue. Several countries in the region have introduced health care reforms which are having a positive impact on the market growth. Moreover, healthcare reforms in the US have also helped reduce the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms are likely to have a positive impact on healthcare insurance and also reduce hospital stay and overall medical expenses, which will boost this market's growth in the region.

The global Hemophilia Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hemophilia Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Hemophilia Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hemophilia Drugs in these regions.

This research report categorizes the global Hemophilia Drugs market by top players/brands, region, type and end user. This report also studies the global Hemophilia Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

- Baxalta

- Bayer

- CSL Behring

- Pfizer

- Alnylam Pharmaceuticals

- BioMarin

- Catalyst Biosciences

- Dimension Therapeutics

- F. Hoffmann-La Roche

- Grifols

- Octapharma

- Sangamo Biosciences

- Spark Therapeutics

- Swedish Orphan Biovitrum

Market size by Product

- Hemophilia A

- Inhibitors

- Hemophilia B

- Von Willebrand Disease

Market size by End User

- Recombinant Therapies

- Plasma-Derived Therapies

Market size by Region

- North America

- - United States

- - Canada

- - Mexico

- Asia-Pacific

- - China

- - India

- - Japan

- - South Korea

- - Australia

- - Indonesia

- - Singapore

- - Malaysia

- - Philippines

- - Thailand

- - Vietnam

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Spain

- - Russia

- Central & South America

- - Brazil

- - Rest of Central & South America

- Middle East & Africa

- - GCC Countries

- - Turkey

- - Egypt

- - South Africa

The study objectives of this report are:

- To study and analyze the global Hemophilia Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.

- To understand the structure of Hemophilia Drugs market by identifying its various subsegments.

- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

- Focuses on the key global Hemophilia Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.

- To project the value and sales volume of Hemophilia Drugs submarkets, with respect to key regions.

- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Hemophilia Drugs are as follows:

- History Year: 2014-2018

- Base Year: 2018

- Estimated Year: 2019

- Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hemophilia Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global Hemophilia Drugs Market Insights, Forecast to 2025

Table of Contents
1 Study Coverage
1.1 Hemophilia Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Hemophilia Drugs Market Size Growth Rate by Product
1.4.2 Hemophilia A
1.4.3 Inhibitors
1.4.4 Hemophilia B
1.4.5 Von Willebrand Disease
1.5 Market by End User
1.5.1 Global Hemophilia Drugs Market Size Growth Rate by End User
1.5.2 Recombinant Therapies
1.5.3 Plasma-Derived Therapies
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hemophilia Drugs Market Size
2.1.1 Global Hemophilia Drugs Revenue 2014-2025
2.1.2 Global Hemophilia Drugs Sales 2014-2025
2.2 Hemophilia Drugs Growth Rate by Regions
2.2.1 Global Hemophilia Drugs Sales by Regions
2.2.2 Global Hemophilia Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Hemophilia Drugs Sales by Manufacturers
3.1.1 Hemophilia Drugs Sales by Manufacturers
3.1.2 Hemophilia Drugs Sales Market Share by Manufacturers
3.1.3 Global Hemophilia Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Hemophilia Drugs Revenue by Manufacturers
3.2.1 Hemophilia Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Hemophilia Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Hemophilia Drugs Price by Manufacturers
3.4 Hemophilia Drugs Manufacturing Base Distribution, Product Types
3.4.1 Hemophilia Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hemophilia Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Hemophilia Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Hemophilia Drugs Sales by Product
4.2 Global Hemophilia Drugs Revenue by Product
4.3 Hemophilia Drugs Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Hemophilia Drugs Breakdown Data by End User
6 North America
6.1 North America Hemophilia Drugs by Countries
6.1.1 North America Hemophilia Drugs Sales by Countries
6.1.2 North America Hemophilia Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Hemophilia Drugs by Product
6.3 North America Hemophilia Drugs by End User
7 Europe
7.1 Europe Hemophilia Drugs by Countries
7.1.1 Europe Hemophilia Drugs Sales by Countries
7.1.2 Europe Hemophilia Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hemophilia Drugs by Product
7.3 Europe Hemophilia Drugs by End User
8 Asia Pacific
8.1 Asia Pacific Hemophilia Drugs by Countries
8.1.1 Asia Pacific Hemophilia Drugs Sales by Countries
8.1.2 Asia Pacific Hemophilia Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Hemophilia Drugs by Product
8.3 Asia Pacific Hemophilia Drugs by End User
9 Central & South America
9.1 Central & South America Hemophilia Drugs by Countries
9.1.1 Central & South America Hemophilia Drugs Sales by Countries
9.1.2 Central & South America Hemophilia Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Hemophilia Drugs by Product
9.3 Central & South America Hemophilia Drugs by End User
10 Middle East and Africa
10.1 Middle East and Africa Hemophilia Drugs by Countries
10.1.1 Middle East and Africa Hemophilia Drugs Sales by Countries
10.1.2 Middle East and Africa Hemophilia Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Hemophilia Drugs by Product
10.3 Middle East and Africa Hemophilia Drugs by End User
11 Company Profiles
11.1 Baxalta
11.1.1 Baxalta Company Details
11.1.2 Company Business Overview
11.1.3 Baxalta Hemophilia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Baxalta Hemophilia Drugs Products Offered
11.1.5 Baxalta Recent Development
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Company Business Overview
11.2.3 Bayer Hemophilia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Bayer Hemophilia Drugs Products Offered
11.2.5 Bayer Recent Development
11.3 CSL Behring
11.3.1 CSL Behring Company Details
11.3.2 Company Business Overview
11.3.3 CSL Behring Hemophilia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 CSL Behring Hemophilia Drugs Products Offered
11.3.5 CSL Behring Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Company Business Overview
11.4.3 Pfizer Hemophilia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Pfizer Hemophilia Drugs Products Offered
11.4.5 Pfizer Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Company Business Overview
11.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Alnylam Pharmaceuticals Hemophilia Drugs Products Offered
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 BioMarin
11.6.1 BioMarin Company Details
11.6.2 Company Business Overview
11.6.3 BioMarin Hemophilia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.6.4 BioMarin Hemophilia Drugs Products Offered
11.6.5 BioMarin Recent Development
11.7 Catalyst Biosciences
11.7.1 Catalyst Biosciences Company Details
11.7.2 Company Business Overview
11.7.3 Catalyst Biosciences Hemophilia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Catalyst Biosciences Hemophilia Drugs Products Offered
11.7.5 Catalyst Biosciences Recent Development
11.8 Dimension Therapeutics
11.8.1 Dimension Therapeutics Company Details
11.8.2 Company Business Overview
11.8.3 Dimension Therapeutics Hemophilia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Dimension Therapeutics Hemophilia Drugs Products Offered
11.8.5 Dimension Therapeutics Recent Development
11.9 F. Hoffmann-La Roche
11.9.1 F. Hoffmann-La Roche Company Details
11.9.2 Company Business Overview
11.9.3 F. Hoffmann-La Roche Hemophilia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.9.4 F. Hoffmann-La Roche Hemophilia Drugs Products Offered
11.9.5 F. Hoffmann-La Roche Recent Development
11.10 Grifols
11.10.1 Grifols Company Details
11.10.2 Company Business Overview
11.10.3 Grifols Hemophilia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Grifols Hemophilia Drugs Products Offered
11.10.5 Grifols Recent Development
11.11 Octapharma
11.12 Sangamo Biosciences
11.13 Spark Therapeutics
11.14 Swedish Orphan Biovitrum
12 Future Forecast
12.1 Hemophilia Drugs Market Forecast by Regions
12.1.1 Global Hemophilia Drugs Sales Forecast by Regions 2019-2025
12.1.2 Global Hemophilia Drugs Revenue Forecast by Regions 2019-2025
12.2 Hemophilia Drugs Market Forecast by Product
12.2.1 Global Hemophilia Drugs Sales Forecast by Product 2019-2025
12.2.2 Global Hemophilia Drugs Revenue Forecast by Product 2019-2025
12.3 Hemophilia Drugs Market Forecast by End User
12.4 North America Hemophilia Drugs Forecast
12.5 Europe Hemophilia Drugs Forecast
12.6 Asia Pacific Hemophilia Drugs Forecast
12.7 Central & South America Hemophilia Drugs Forecast
12.8 Middle East and Africa Hemophilia Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hemophilia Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables and Figures
Figure Hemophilia Drugs Product Picture
Table Hemophilia Drugs Market Segments
Table Key Manufacturers Hemophilia Drugs Covered
Table Global Hemophilia Drugs Market Size Growth Rate by Product 2019-2025 (K MT) & (Million US$)
Figure Global Hemophilia Drugs Sales Market Share by Product 2014-2025
Figure Hemophilia A Product Picture
Table Major Manufacturers of Hemophilia A
Figure Inhibitors Product Picture
Table Major Manufacturers of Inhibitors
Figure Hemophilia B Product Picture
Table Major Manufacturers of Hemophilia B
Figure Von Willebrand Disease Product Picture
Table Major Manufacturers of Von Willebrand Disease
Table Global Hemophilia Drugs Market Size Growth Rate by End User 2019-2025 (K MT)
Figure Recombinant Therapies
Figure Plasma-Derived Therapies
Figure Hemophilia Drugs Report Years Considered
Figure Global Hemophilia Drugs Market Size 2014-2025 (Million US$)
Figure Global Hemophilia Drugs Sales 2014-2025 (K MT)
Table Global Hemophilia Drugs Market Size by Regions 2014-2019 (K MT) & (Million US$)
Table Global Hemophilia Drugs Sales by Regions 2014-2019 (K MT)
Table Global Hemophilia Drugs Sales Market Share by Regions 2014-2019
Figure Global Hemophilia Drugs Sales Market Share by Regions 2014-2019
Figure 2018 Global Hemophilia Drugs Sales Market Share by Regions
Table Global Hemophilia Drugs Revenue by Regions 2014-2019 (Million US$)
Table Global Hemophilia Drugs Revenue Market Share by Regions 2014-2019
Figure Global Hemophilia Drugs Revenue Market Share by Regions 2014-2019
Figure 2018 Global Hemophilia Drugs Revenue Market Share by Regions
Table Global Hemophilia Drugs Sales by Manufacturers (2014-2019) (K MT)
Table Global Hemophilia Drugs Sales Share by Manufacturers (2014-2019)
Figure Global Hemophilia Drugs Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Hemophilia Drugs Revenue by Manufacturers (2014-2019) (Million USD)
Table Hemophilia Drugs Revenue Share by Manufacturers (2014-2019)
Figure Hemophilia Drugs Value Share by Manufacturers in 2018
Table Key Manufacturers Hemophilia Drugs Price (2014-2019) (USD/MT)
Table Hemophilia Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Hemophilia Drugs Product Type
Table Date of International Manufacturers Enter into Hemophilia Drugs Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Hemophilia Drugs Sales by Product (2014-2019) (K MT)
Table Global Hemophilia Drugs Sales Share by Product (2014-2019)
Figure Global Hemophilia Drugs Sales Market Share by Product (2014-2019)
Figure Global Hemophilia Drugs Sales Market Share by Product in 2018
Table Global Hemophilia Drugs Revenue by Product (2014-2019) (Million US$)
Table Global Hemophilia Drugs Revenue Share by Product (2014-2019)
Figure Global Hemophilia Drugs Revenue Market Share by Product (2014-2019)
Figure Global Hemophilia Drugs Revenue Market Share by Product in 2018
Table Hemophilia Drugs Price by Product 2014-2019 (USD/MT)
Table Global Hemophilia Drugs Sales by End User (2014-2019) (K MT)
Table Global Hemophilia Drugs Sales Share by End User (2014-2019)
Figure Global Sales Hemophilia Drugs Market Share by End User (2014-2019)
Figure Global Sales Hemophilia Drugs Market Share by End User in 2018
Figure North America Hemophilia Drugs Sales Growth Rate 2014-2019 (K MT)
Figure North America Hemophilia Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table North America Hemophilia Drugs Sales by Countries (2014-2019) (K MT)
Table North America Hemophilia Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 North America Hemophilia Drugs Sales Market Share by Countries
Table North America Hemophilia Drugs Revenue by Countries (2014-2019) (Million US$)
Table North America Hemophilia Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 North America Hemophilia Drugs Revenue Market Share by Countries
Figure United States Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure United States Hemophilia Drugs Revenue Growth Rate (2014-2019) (K MT)
Figure Canada Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Canada Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Mexico Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table North America Hemophilia Drugs Sales by Product (2014-2019) (K MT)
Table North America Hemophilia Drugs Sales Market Share by Product (2014-2019)
Figure 2018 North America Hemophilia Drugs Market Share by Product
Table North America Hemophilia Drugs Sales by End User (2014-2019) (K MT)
Table North America Hemophilia Drugs Sales Market Share by End User (2014-2019)
Figure 2018 North America Hemophilia Drugs Market Share by End User
Figure Europe Hemophilia Drugs Sales Growth Rate 2014-2019 (K MT)
Figure Europe Hemophilia Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Europe Hemophilia Drugs Sales by Countries (2014-2019) (K MT)
Table Europe Hemophilia Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Europe Hemophilia Drugs Sales Market Share by Countries
Table Europe Hemophilia Drugs Revenue by Countries (2014-2019) (Million US$)
Table Europe Hemophilia Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Europe Hemophilia Drugs Revenue Market Share by Countries
Figure Germany Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Germany Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure France Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure France Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure UK Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure UK Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Italy Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Russia Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Europe Hemophilia Drugs Sales by Product (2014-2019) (K MT)
Table Europe Hemophilia Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Europe Hemophilia Drugs Market Share by Product
Table Europe Hemophilia Drugs Sales by End User (2014-2019) (K MT)
Table Europe Hemophilia Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Europe Hemophilia Drugs Market Share by End User
Figure Asia Pacific Hemophilia Drugs Sales Growth Rate 2014-2019 (K MT)
Figure Asia Pacific Hemophilia Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific Hemophilia Drugs Sales by Countries (2014-2019) (K MT)
Table Asia Pacific Hemophilia Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Hemophilia Drugs Sales Market Share by Countries
Table Asia Pacific Hemophilia Drugs Revenue by Countries (2014-2019) (Million US$)
Table Asia Pacific Hemophilia Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Hemophilia Drugs Revenue Market Share by Countries
Figure China Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure China Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Japan Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Korea Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure India Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure India Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Australia Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Indonesia Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Malaysia Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Philippines Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Thailand Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Vietnam Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Singapore Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific Hemophilia Drugs Sales by Product (2014-2019) (K MT)
Table Asia Pacific Hemophilia Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Asia Pacific Hemophilia Drugs Market Share by Product
Table Asia Pacific Hemophilia Drugs Sales by End User (2014-2019) (K MT)
Table Asia Pacific Hemophilia Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Asia Pacific Hemophilia Drugs Market Share by End User
Figure Central & South America Hemophilia Drugs Sales Growth Rate 2014-2019 (K MT)
Figure Central & South America Hemophilia Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America Hemophilia Drugs Sales by Countries (2014-2019) (K MT)
Table Central & South America Hemophilia Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Central & South America Hemophilia Drugs Sales Market Share by Countries
Table Central & South America Hemophilia Drugs Revenue by Countries (2014-2019) (Million US$)
Table Central & South America Hemophilia Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Central & South America Hemophilia Drugs Revenue Market Share by Countries
Figure Brazil Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Brazil Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Argentina Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America Hemophilia Drugs Sales by Product (2014-2019) (K MT)
Table Central & South America Hemophilia Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Central & South America Hemophilia Drugs Market Share by Product
Table Central & South America Hemophilia Drugs Sales by End User (2014-2019) (K MT)
Table Central & South America Hemophilia Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Central & South America Hemophilia Drugs Market Share by End User
Figure Middle East and Africa Hemophilia Drugs Sales Growth Rate 2014-2019 (K MT)
Figure Middle East and Africa Hemophilia Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa Hemophilia Drugs Sales by Countries (2014-2019) (K MT)
Table Middle East and Africa Hemophilia Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Hemophilia Drugs Sales Market Share by Countries
Table Middle East and Africa Hemophilia Drugs Revenue by Countries (2014-2019) (Million US$)
Table Middle East and Africa Hemophilia Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Hemophilia Drugs Revenue Market Share by Countries
Figure GCC Countries Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure GCC Countries Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Turkey Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Egypt Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa Hemophilia Drugs Sales Growth Rate (2014-2019) (K MT)
Figure South Africa Hemophilia Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa Hemophilia Drugs Sales by Product (2014-2019) (K MT)
Table Middle East and Africa Hemophilia Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Middle East and Africa Hemophilia Drugs Market Share by Product
Table Middle East and Africa Hemophilia Drugs Sales by End User (2014-2019) (K MT)
Table Middle East and Africa Hemophilia Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Middle East and Africa Hemophilia Drugs Market Share by End User
Table Baxalta Company Details
Table Baxalta Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Baxalta Recent Development
Table Bayer Company Details
Table Bayer Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Bayer Recent Development
Table CSL Behring Company Details
Table CSL Behring Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table CSL Behring Recent Development
Table Pfizer Company Details
Table Pfizer Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Pfizer Recent Development
Table Alnylam Pharmaceuticals Company Details
Table Alnylam Pharmaceuticals Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Alnylam Pharmaceuticals Recent Development
Table BioMarin Company Details
Table BioMarin Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table BioMarin Recent Development
Table Catalyst Biosciences Company Details
Table Catalyst Biosciences Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Catalyst Biosciences Recent Development
Table Dimension Therapeutics Company Details
Table Dimension Therapeutics Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Dimension Therapeutics Recent Development
Table F. Hoffmann-La Roche Company Details
Table F. Hoffmann-La Roche Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table F. Hoffmann-La Roche Recent Development
Table Grifols Company Details
Table Grifols Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Grifols Recent Development
Table Octapharma Company Details
Table Sangamo Biosciences Company Details
Table Spark Therapeutics Company Details
Table Swedish Orphan Biovitrum Company Details
Table Global Hemophilia Drugs Sales Forecast by Regions 2019-2025 (K MT)
Table Global Hemophilia Drugs Sales Market Share Forecast by Regions 2019-2025
Table Global Hemophilia Drugs Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global Hemophilia Drugs Revenue Market Share Forecast by Regions 2019-2025
Table Global Hemophilia Drugs Sales Forecast by Product 2019-2025 (K MT)
Table Global Hemophilia Drugs Sales Market Share Forecast by Product 2019-2025
Table Global Hemophilia Drugs Revenue Forecast by Product 2019-2025 (Million US$)
Table Global Hemophilia Drugs Revenue Market Share Forecast by Product 2019-2025
Table Global Hemophilia Drugs Sales Forecast by End User 2019-2025 (K MT)
Table Global Hemophilia Drugs Sales Market Share Forecast by End User 2019-2025
Figure North America Hemophilia Drugs Sales Growth Rate Forecast (2019-2025) (K MT)
Figure North America Hemophilia Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe Hemophilia Drugs Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Europe Hemophilia Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific Hemophilia Drugs Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Asia Pacific Hemophilia Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America Hemophilia Drugs Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Central & South America Hemophilia Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa Hemophilia Drugs Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Middle East and Africa Hemophilia Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table Hemophilia Drugs Value Chain
Table Hemophilia Drugs Customers List
Table Hemophilia Drugs Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
  • Global (United States, European Union and China) Antithrombotic Drugs Market Research Report 2019-2025
    Published: 22-Jul-2019        Price: US 3280 Onwards        Pages: 110
    Thrombosis is may be defined as the formation of blood clot in the blood vessel or lumen part of the blood vessel. Formation of blood clots inside the blood vessel causes disruption of blood flow and it leads to cause death of cells. Deep vein thrombosis (DVT) is one type of thrombosis and it affects larger muscle of thigh. As a result, it causes pain, swelling in the leg and also it causes pulmonary embolism. Deep vein thrombosis (DVT) and pulmonary embolism collectively called as venous thromb......
  • Global Intravenous Immunoglobulin (IVIg) Market Status (2015-2019) and Forecast (2020-2024) by Region, Product Type & End-Use
    Published: 21-Jul-2019        Price: US 3000 Onwards        Pages: 102
    Summary Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or "lot" of Intravenous Immunoglobulin. The report forecast global Intravenous Immunoglobulin (IVIg) market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2024. The report offer......
  • Global Injectable Anticoagulants Market Status (2015-2019) and Forecast (2020-2024) by Region, Product Type & End-Use
    Published: 21-Jul-2019        Price: US 3000 Onwards        Pages: 91
    Summary The injectable anticoagulants include low molecular weight heparin (LMWH) agents (dalteparin [Fragmin ], enoxaparin [Lovenox ]) and factor Xa inhibitors (fondaparinux [Arixtra ]).In general, the injectable anticoagulants are Food and Drug Administration (FDA)-approved for prophylaxis and/or treatment of venous thromboembolism. The report forecast global Injectable Anticoagulants market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 202......
  • Global Low Molecular Weight Heparin Market Status (2015-2019) and Forecast (2020-2024) by Region, Product Type & End-Use
    Published: 20-Jul-2019        Price: US 3000 Onwards        Pages: 110
    Summary Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage. Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined ......
  • Global Low Molecular Weight Heparin Market Research Report 2012-2024
    Published: 19-Jul-2019        Price: US 2320 Onwards        Pages: 82
    Summary Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage. Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined ......
  • Global Intravenous Immunoglobulin (IVIg) Market Research Report 2012-2024
    Published: 17-Jul-2019        Price: US 1960 Onwards        Pages: 74
    Summary Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or "lot" of Intravenous Immunoglobulin. The global Intravenous Immunoglobulin (IVIg) market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the......
  • Global Injectable Anticoagulants Market Research Report 2012-2024
    Published: 17-Jul-2019        Price: US 1880 Onwards        Pages: 67
    Summary The injectable anticoagulants include low molecular weight heparin (LMWH) agents (dalteparin [Fragmin ], enoxaparin [Lovenox ]) and factor Xa inhibitors (fondaparinux [Arixtra ]).In general, the injectable anticoagulants are Food and Drug Administration (FDA)-approved for prophylaxis and/or treatment of venous thromboembolism. The global Injectable Anticoagulants market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define,......
  • Global Factor VIII Deficiency Treatment Market Size, Status and Forecast 2019-2025
    Published: 16-Jul-2019        Price: US 3900 Onwards        Pages: 101
    Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells outside the liver across the body. This protein mixes in the bloodstream in an inactive form, and binds to another molecule called von Willebrand factor, until a damage to blood vessels occur......
  • Global Sickle-cell Anemia Therapeutics Market Size, Status and Forecast 2019-2025
    Published: 15-Jul-2019        Price: US 3900 Onwards        Pages: 99
    Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS). In the last several years, global market of Sickle Cell Anemia Therapeutics developed rapidly, with an average growth rate of 13.32% during 2013 to 2017. I......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs